Targeting interleukin-1β for pain

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 5, 2011, Pages 571-575

  Pillarisetti, Sivaram ^a  

^a Kareus Therapeutics   (United States)

Author keywords

Analgesic; Hyperalgesia; Inflammation; Interleukin 1; Neuropathy; Pain

Indexed keywords

CYCLOOXYGENASE 2; GEVOKIZUMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; NERVE GROWTH FACTOR; PROSTAGLANDIN E2; PURINERGIC P2X7 RECEPTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTICLE; ASTROCYTE; CENTRAL NERVOUS SYSTEM; CYTOKINE PRODUCTION; DRUG TARGETING; HUMAN; HYPERALGESIA; INFLAMMATION; MACROPHAGE; MICROGLIA; MICROVASCULAR ENDOTHELIAL CELL; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; PAIN; PROTEIN EXPRESSION; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION;

EID: 79960019059     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711796234998     Document Type: Article

References (57)

1. Dinarello, C.A. IL-1: discoveries, controversies and future directions. Eur. J. Immunol., 2010, 40(3), 599-606.
2. Braddock, M.; Quinn, A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat. Rev. Drug Discov., 2004, 3, 330-339.
3. Martinon, F.; Tschopp, J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ., 2007, 14, 10-22.
4. Schönbeck, U.; Mach, F.; Libby, P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1- independent pathway of IL-1 beta processing. J. Immunol., 1998, 161(7), 3340-3346.
5. Maedler, K.; Dharmadhikari, G.; Schumann, D.M.; Størling, J. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin. Biol. Ther., 2009, 9(9), 1177-1188.
6. Dinarello, C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol., 2009, 27, 519-550.
7. Allan, S.M.; Tyrrell, P.J.; Rothwell, N.J. Interleukin-1 and neuronal injury. Nat. Rev. Immunol., 2005, 5(8), 629-640.
8. Parnet, P.; Amindari, S.; Wu, C.; Brunke-Reese, D.; Goujon, E.; Weyhenmeyer, J.A.; Dantzer, R.; Kelley, K.W. Expression of type I and type II interleukin-1 receptors in mouse brain. Brain Res. Mol. Brain Res., 1994, 27(1), 63-70.
9. Patel, H.C.; Boutin, H.; Allan, S.M. Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. Ann. NY Acad. Sci., 2003, 992, 39-47.
10. Ching, S.; Zhang, H; Belevych, N.; He, L.; Lai, W.; Pu, X.A.; Jaeger, L.B.; Chen, Q.; Quan, N. Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration. J. Neurosci., 2007, 27(39), 10476-10486.
11. Ferrari, D.; Pizzirani, C.; Adinolfi, E.; Lemoli, R.M.; Curti, A.; Idzko, M.; Panther, E.; Di Virgilio, F. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol., 2006, 176(7), 3877-3883.
12. Chessell, I.P.; Hatcher, J.P.; Bountra, C.; Michel, A.D.; Hughes, J.P.; Green, P.; Egerton, J.; Murfin, M.; Richardson, J.; Peck, W.L.; Grahames, C.B.; Casula, M.A.; Yiangou, Y.; Birch, R.; Anand, P.; Buell, G.N. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain, 2005, 114(3), 386-396.
13. Kawasaki, Y.; Xu, Z.Z.; Wang, X.; Park, J.Y.; Zhuang, Z.Y.; Tan, P.H.; Gao, Y.J.; Roy, K.; Corfas, G.; Lo, E.H.; Ji, R.R. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat. Med., 2008, 14(3), 331-336.
14. Watkins, L.R.; Maier, S.F.; Goehler, L.E. Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain, 1995, 63, 289-302.
15. Watkins, L.R.; Maier, S.F. Beyond Neurons: Evidence That Immune and Glial Cells Contribute to Pathological Pain States. Physiol. Rev., 2002, 82, 981-1011.
16. Milligan, E.D.; Twining, C.; Chacur, M.; Biedenkapp, J.; O'Connor, K.; Poole, S.; Tracey, K.; Martin, D.; Maier, S.F.; Watkins, L.R. Spinal Glia and Proinflammatory Cytokines Mediate Mirror-Image Neuropathic Pain in Rats. J. Neurosci., 2003, 23, 1026-1040.
17. Ruohonen, S.; Jagodi, M.; Khademi, M.; Taskinen, H.S.; Ojala, P.; Olsson, T.; Röyttä, M. Contralateral non-operated nerve to transected rat sciatic nerve shows increased expression of IL-1beta, TGF-beta1, TNF-alpha, and IL-10. J. Neuroimmunol., 2002, 132(1-2), 11-17.
18. Apkarian, A.V.; Lavarello, S.; Randolf, A.; Berra, H.H.; Chialvo, D.R.; Besedovsky, H.O.; del Rey, A. Expression of IL-1beta in supraspinal brain regions in rats with neuropathic pain. Neurosci. Lett., 2006, 407(2), 176-181.
19. Wang, Z.; Wang, J.; Li, X.; Yuan, Y.; Fan, G. Interleukin-1 beta of Red nucleus involved in the development of allodynia in spared nerve injury rats. Exp. Brain Res., 2008, 188(3), 379-384.
20. Solovieva, S.; Leino-Arjas, P.; Saarela, J.; Luoma, K.; Raininko, R.; Riihimäki, H. Possible association of interleukin 1 gene locus polymorphisms with low back pain. Pain, 2004, 109(1-2), 8-19.
21. Alexander, G.M.; van Rijn, M.A.; van Hilten, J.J.; Perreault, M.J.; Schwartzman, R.J. Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS Pain, 2005, 116(3), 213-219.
22. Ferreira, S.H.; Lorenzetti, B.B.; Bristow, A.F.; Poole, S. Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature, 1988, 334(6184), 698-700.
23. Reeve, A.J.; Patel, S.; Fox, A.; Walker, K.; Urban, L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. Eur. J. Pain, 2000, 4, 247-257.
24. Sommer, C.; Petrausch, S.; Lindenlaub, T.; Toyka, K.V. Neutralizing antibodies to interleukin 1-receptor reduce pain associated behavior in mice with experimental neuropathy. Neurosci. Lett., 1999, 270(1), 25-28.
25. Twining, C.M.; Sloane, E.M.; Milligan, E.D.; Chacur, M.; Martin, D.; Poole, S.; Marsh, H.; Maier, S.F.; Watkins, L.R. Peri-sciatic pro inflammatory cytokines, reactive oxygen species, and complement induce mirror-image neuropathic pain in rats. Pain, 2004, 110(1-2), 299-309.
26. Cunha, J.M.; Cunha, F.Q.; Poole, S.; Ferreira, S.H. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. Br. J. Pharmacol., 2000, 130(6), 1418-1424.
27. Li, W.W.; Sabsovich, I.; Guo, T.Z.; Zhao, R.; Kingery, W.S.; Clark, J.D. The role of enhanced cutaneous IL-1beta signaling in a rat tibia fracture model of complex regional pain syndrome. Pain, 2009, 144(3), 303-313.
28. Baamonde, A.; Curto-Reyes, V.; Juárez, L.; Meana, A.; Hidalgo, A.; Menéndez, L. Antihyperalgesic effects induced by the IL-1 receptor antagonist anakinra and increased IL-1beta levels in inflamed and osteosarcoma-bearing mice. Life Sci., 2007, 81(8), 673-682.
29. Wolf, G.; Gabay, E.; Tal, M.; Yirmiya, R.; Shavit, Y. Genetic impairment of interleukin-1 signaling attenuates neuropathic pain, autotomy, and spontaneous ectopic neuronal activity, following nerve injury in mice. Pain, 2006, 120(3), 315-324.
30. Wolf, G.; Yirmiya, R.; Goshen, I.; Iverfeldt, K.; Holmlund, L.; Takeda, K.; Shavit, Y. Impairment of interleukin-1 (IL-1) signaling reduces basal pain sensitivity in mice: genetic, pharmacological and developmental aspects. Pain, 2003, 104(3), 471-480.
31. Wolf, G.; Livshits, D.; Beilin, B.; Yirmiya, R.; Shavit, Y. Interleukin-1 signaling is required for induction and maintenance of postoperative incisional pain: genetic and pharmacological studies in mice. Brain Behav. Immun., 2008, 22(7), 1072-1077.
32. Shavit, Y.; Wolf, G.; Goshen, I.; Livshits, D.; Yirmiya, R. Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance. Pain, 2005, 115(1-2), 50-59.
33. Gul, H.; Yildiz, O.; Dogrul, A.; Yesilyurt, O.; Isimer, A. The interaction between IL-1beta and morphine: possible mechanism of the deficiency of morphine-induced analgesia in diabetic mice. Pain, 2000, 89(1), 39-45.
34. Samad, T.A.; Moore, K.A.; Sapirstein, A.; Billet, S.; Allchorne, A.; Poole, S.; Bonventre, J.V.; Woolf, C.J. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature, 2001, 410(6827), 471-475.
35. Ahn, D.K.; Chae, J.M.; Choi, H.S.; Kyung, H.M.; Kwon, O.W.; Park, H.S.; Youn, D.H.; Bae, Y.C. Central cyclooxygenase inhibitors reduced IL-1beta-induced hyperalgesia in temporomandibular joint of freely moving rats. Pain, 2005, 117(1-2), 204-213.
36. Safieh-Garabedian, B.; Poole, S.; Allchorne, A.; Winter, J.; Woolf, C.J. Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br. J. Pharmacol., 1995, 115(7), 1265-1275.
37. Lindholm, D.; Heumann, R.; Meyer, M.; Thoenen, H. Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. Nature, 1987, 330(6149), 658-659.
38. Binshtok, A.M.; Wang, H.; Zimmermann, K.; Amaya, F.; Vardeh, D.; Shi, L.; Brenner, G.J.; Ji, R.R.; Bean, B.P.; Woolf, C.J.; Samad, T.A. Nociceptors are interleukin-1beta sensors. J. Neurosci., 2008, 28(52), 14062-14073.
39. Zhang, R.X.; Li, A.; Liu, B.; Wang, L.; Ren, K.; Zhang, H.; Berman, B.M.; Lao, L. IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in rats. Pain, 2008, 135(3), 232-239.
40. Sperlágh, B.; Baranyi, M.; Haskó, G.; Vizi, E.S. Potent effect of interleukin-1 beta to evoke ATP and adenosine release from rat hippocampal slices. J. Neuroimmunol., 2004, 151(1-2), 33-39.
41. Gao, X.; Kim, H.K.; Chung, J.M.; Chung, K. Enhancement of NMDA receptor phosphorylation of the spinal dorsal horn and nucleus gracilis neurons in neuropathic rats. Pain, 2005, 116(1-2), 62-72.
42. Ultenius, C; Linderoth, B.; Meyerson, B.A.; Wallin, J. Spinal NMDA receptor phosphorylation correlates with the presence of neuropathic signs following peripheral nerve injury in the rat. Neuroscience Lett., 2006, 399(1-2), 85-90.
43. Guile, S.D.; Alcaraz, L.; Birkinshaw, T.N.; Bowers, K.C.; Ebden M.R.; Furber, M.; Stocks, M.J. Antagonists of the P2X(7) receptor. From lead identification to drug development. J. Med. Chem., 2009, 52(10), 3123-3141.
44. Friedle, S.A.; Curet, M.A.; Watters, J.J. Recent patents on novel P2X(7) receptor antagonists and their potential for reducing central nervous system inflammation. Recent Pat. CNS Drug Discov., 2010, 5(1), 35-45.
45. Gunosewoyo, H.; Kassiou, M. P2X purinergic receptor ligands: recently patented compounds. Expert Opin. Ther. Pat., 2010, 20, 625-646.
46. Kulkarni, S.S.; Kulkarni, V.M. Three-dimensional quantitative structure-activity relationship of interleukin 1-beta converting enzyme inhibitors: a comparative molecular field analysis study. J. Med. Chem., 1999, 42(3), 373-380.
47. Rodríguez, D.; Morrison, C.J.; Overall, CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim. Biophys. Acta, 2010, 1803(1), 39-54.
48. Chevalier, X.; Goupille, P.; Beaulieu, A.D.; Burch, F.X.; Bensen, W.G.; Conrozier, T.; Loeuille, D.; Kivitz, A.J.; Silver, D.; Appleton, B.E. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J. Rheumatol, 2005, 32(7), 1317-1323.
49. Roell, M.K.; Issafras, H.; Bauer, R.J.; Michelson, K.S.; Mendoza, N.; Vanegas, S.I.; Gross, L.M.; Larsen, P.D.; Bedinger, D.H.; Bohmann, D.J.; Nonet, G.H.; Liu, N.; Lee, S.R.; Handa, M.; Kantak, S.S.; Horwitz, A.H.; Hunter, J.J.; Owyang, A.M.; Mirza, A.M.; Corbin, J.A.; White, M.L. A kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates IL-1p activity. J. Biol. Chem., 2010, 285(27), 20607-20614.
50. Vigers, G.P.A.; Anderson, L.J.; Caffes, P.; Brandhuber, B.J. Nature, 1997, 386, 190-194.
51. Vigers, G.P.; Caffes, P.; Evans, R.J.; Thompson, R.C.; Eisenberg, S.P.; Brandhuber, B.J. X-ray structure of interleukin-1 receptor antagonist at 2.0-A resolution. J. Biol. Chem., 1994, 269(17), 12874-12879.
52. Schreuder, H.; Tardif, C; Trump-Kallmeyer, S.; Soffientini, A.; Sarubbi, E.; Akeson, A.; Bowlin, T.; Yanofsky, S.; Barrett, R.W. Nature, 1997, 386, 194-200.
53. Poole, S.; Bristow, A.F.; Lorenzetti, B.B.; Das, R.E.; Smith, T.W.; Ferreira, S.H. Peripheral analgesic activities of peptides related to alpha-melanocyte stimulating hormone and interleukin-1 beta 193-195. Br. J. Pharmacol, 1992, 106(2), 489-492.
54. Oluyomi, A.O.; Poole, S.; Smith, T.W.; Hart, S.L. Antinociceptive activity of peptides related to interleukin-1 beta-(193-195), Lys-Pro-Thr. Eur. J. Pharmacol, 1994, 258(1-2), 131-138.
55. Yanofsky, S.D.; Baldwin, D.N.; Butler, J.H.; Holden, F.R.; Jacobs, J.W.; Balasubramanian, P.; Chinn, J.P.; Cwirla, S.E.; Peters-Bhatt, E.; Whitehorn, E.A.; Tate, E.H.; Akeson, A.; Bowlin, T.L.; Dower, W.J.; Barrett, R.W. High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc. Natl. Acad. Sci. USA, 1996, 93(14), 7381-7386.
56. Sarabu, R.; Cooper, J.P.; Cook, CM.; Gillespie, P.; Perrotta, A.V.; Olson, G.L. Design and synthesis of small molecule interleukin-1 receptor antagonists based on a benzene template. Drug Des. Discov., 1998, 15(3), 191-198.
57. Mertens, M.; Singh, J.A. Anakinra for rheumatoid arthritis: a systematic review. J. Rheumatol, 2009, 36, 1118-1125.